TrialBMJ open2017

Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.

Hai-Bo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.